Clinical Trial Update: Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated whether depleting regulatory T cells could enhance dendritic cell–based vaccines in stage IV melanoma; the study has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Radboud University Medical Center | Conditions: Melanoma | Phase 1, Phase 2 | Status: COMPLETED